STOCK TITAN

[Form 4] Neuphoria Therapeutics Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Positive)
Form Type
4

Neuphoria Therapeutics Inc. (NEUP) disclosed an insider purchase on a Form 4. Reporting persons tied to Lynx1 Master Fund LP bought 639,110 shares of common stock on 10/21/2025 at a weighted average price of $5.137. The filing notes the trades occurred across prices from $4.96 to $5.20. After the transaction, the filing reports 875,328 shares beneficially owned on an indirect basis. The reporting person’s relationship box indicates Director.

The filing explains that the securities are held by Lynx1 Master Fund LP, with Lynx1 Capital Management LP as investment manager and Weston Nichols as the sole member of the manager’s general partner, and includes customary beneficial ownership disclaimers.

Neuphoria Therapeutics Inc. (NEUP) ha comunicato un acquisto da insider su un Modulo 4. Le persone che riportano legami con Lynx1 Master Fund LP hanno acquistato 639.110 azioni ordinarie il 21/10/2025 ad un prezzo medio ponderato di 5,137 USD. La comunicazione indica che le operazioni sono avvenute a prezzi compresi tra 4,96 e 5,20 USD. Dopo la transazione, la comunicazione riporta 875.328 azioni detenute indirettamente a titolo beneficiario. Il campo relativo al rapporto del riportante indica Direttore.

La comunicazione spiega che i titoli sono detenuti da Lynx1 Master Fund LP, con Lynx1 Capital Management LP come gestore degli investimenti e Weston Nichols come unico membro del general partner del gestore, e include avvertenze standard sulla proprietà beneficiaria.

Neuphoria Therapeutics Inc. (NEUP) divulgó una compra interna en un Formulario 4. Las personas reportantes vinculadas a Lynx1 Master Fund LP compraron 639,110 acciones de acciones ordinarias el 21/10/2025 a un precio medio ponderado de 5,137 USD. El escrito señala que las operaciones ocurrieron a precios que oscilan entre 4,96 y 5,20 USD. Después de la transacción, el escrito reporta 875.328 acciones beneficiariamente poseídas de manera indirecta. El campo de relación del informante indica Director.

El escrito explica que los valores son mantenidos por Lynx1 Master Fund LP, con Lynx1 Capital Management LP como administrador de inversiones y Weston Nichols como el único miembro del socio general del administrador, e incluye cláusulas habituales de divulgación de propiedad beneficiosa.

Neuphoria Therapeutics Inc. (NEUP)가 Form 4에서 내부자 매매를 공시했습니다. Lynx1 Master Fund LP에 연결된 신고자들이 639,110주의 보통주를 2025-10-21가중평균 5.137달러의 가격으로 매수했습니다. 공시에는 거래가 4.96~5.20달러 범위의 가격으로 이뤄졌다고 기록되어 있습니다. 거래 후, 신고에 따르면 875,328주를 간접적으로 수익적으로 보유하게 되었습니다. 신고자의 관계란에 이사로 표시되어 있습니다.

공시는 주식이 Lynx1 Master Fund LP에 의해 보유되며, Lynx1 Capital Management LP가 투자 관리자로, 관리자의 일반 파트너의 유일한 구성원은 Weston Nichols이며, 일반적인 수익 소유권 면책 조항이 포함되어 있습니다.

Neuphoria Therapeutics Inc. (NEUP) a déclaré un achat d’initié dans le cadre d’un Formulaire 4. Les personnes déclarantes liées à Lynx1 Master Fund LP ont acheté 639 110 actions ordinaires le 21/10/2025 à un prix moyen pondéré de 5,137 USD. Le document indique que les transactions ont eu lieu sur des prix allant de 4,96 à 5,20 USD. Après la transaction, le document indique 875 328 actions détenues de manière bénéficiaire et indirecte. La case relation du déclarant indique Directeur.

Le document explique que les titres sont détenus par Lynx1 Master Fund LP, Lynx1 Capital Management LP en tant que gestionnaire d’investissement et Weston Nichols comme seul membre du partenaire général du gestionnaire, et comprend les clauses habituelles de divulgation de la propriété bénéficiaire.

Neuphoria Therapeutics Inc. (NEUP) hat einen Insiderkauf über ein Formular 4 offengelegt. Meldende Personen, verbunden mit Lynx1 Master Fund LP, kauften 639.110 Aktien Stammaktien am 21.10.2025 zu einem gewichteten Durchschnittspreis von 5,137 USD. Die Einreichung vermerkt, dass die Trades zu Preisen von 4,96 bis 5,20 USD stattfanden. Nach der Transaktion meldet die Einreichung 875.328 Aktien, die indirekt wohlerworbene Eigentümer sind. Das Beziehungsfeld des meldenden Persons gibt Direktor an.

Die Einreichung erklärt, dass die Wertpapiere von Lynx1 Master Fund LP gehalten werden, wobei Lynx1 Capital Management LP als Investmentmanager fungiert und Weston Nichols als einziges Mitglied des Generalpartners des Managers aufgeführt ist, und enthält übliche Hinweise zur vorteilhaften Eigentümerschaft.

Ne хуж لا يوجد ترجمة عربية دقيقة للاسم التجاري كما هي دون معلومات إضافية. ومع ذلك، النص التالي سيظل كالتالي: Neuphoria Therapeutics Inc. (NEUP) أعلنت عن شراء من الداخل في نموذج 4. الأشخاص المبلغ عنهم المرتبطون بـ Lynx1 Master Fund LP اشتروا 639,110 سهماً عادياً في 21/10/2025 بسعر متوسط وزني قدره 5.137 دولار. تشير المقالة إلى أن التداولات تمت ضمن أسعار من 4.96 إلى 5.20 دولار. بعد الصفقة، تقر المؤلفة بأن 875,328 سهماً يمتلكها المستفيد بشكل غير مباشر. يُظهر خانة علاقة المبلغ بأن مدير.

تشرح الوثيقة أن الأوراق مملوكة ل Lynx1 Master Fund LP، مع Lynx1 Capital Management LP كمدير استثماري و Weston Nichols كعضو وحيد في الشريك العام للمدير، وتضم إخلاءات عامة بخصوص الملكية المستفيدة.

Neuphoria Therapeutics Inc. (NEUP) 披露了在 Form 4 上的内部人员购买。与 Lynx1 Master Fund LP 相关的申报人购买了 639,110 股普通股,交易日为 2025/10/21,成交的 加权平均价格为 5.137 美元。申报文件记载交易发生在价格区间 4.96 至 5.20 美元。交易完成后,申报文件显示通过间接方式持有的 875,328 股受益所有权。申报人的关系框显示为 董事

文件解释,这些证券由 Lynx1 Master Fund LP 持有,Lynx1 Capital Management LP 作为投资经理,经理的普通合伙人唯一成员为 Weston Nichols,并包含通常的受益所有权免责声明。

Positive
  • None.
Negative
  • None.

Insights

Analyzing...

Neuphoria Therapeutics Inc. (NEUP) ha comunicato un acquisto da insider su un Modulo 4. Le persone che riportano legami con Lynx1 Master Fund LP hanno acquistato 639.110 azioni ordinarie il 21/10/2025 ad un prezzo medio ponderato di 5,137 USD. La comunicazione indica che le operazioni sono avvenute a prezzi compresi tra 4,96 e 5,20 USD. Dopo la transazione, la comunicazione riporta 875.328 azioni detenute indirettamente a titolo beneficiario. Il campo relativo al rapporto del riportante indica Direttore.

La comunicazione spiega che i titoli sono detenuti da Lynx1 Master Fund LP, con Lynx1 Capital Management LP come gestore degli investimenti e Weston Nichols come unico membro del general partner del gestore, e include avvertenze standard sulla proprietà beneficiaria.

Neuphoria Therapeutics Inc. (NEUP) divulgó una compra interna en un Formulario 4. Las personas reportantes vinculadas a Lynx1 Master Fund LP compraron 639,110 acciones de acciones ordinarias el 21/10/2025 a un precio medio ponderado de 5,137 USD. El escrito señala que las operaciones ocurrieron a precios que oscilan entre 4,96 y 5,20 USD. Después de la transacción, el escrito reporta 875.328 acciones beneficiariamente poseídas de manera indirecta. El campo de relación del informante indica Director.

El escrito explica que los valores son mantenidos por Lynx1 Master Fund LP, con Lynx1 Capital Management LP como administrador de inversiones y Weston Nichols como el único miembro del socio general del administrador, e incluye cláusulas habituales de divulgación de propiedad beneficiosa.

Neuphoria Therapeutics Inc. (NEUP)가 Form 4에서 내부자 매매를 공시했습니다. Lynx1 Master Fund LP에 연결된 신고자들이 639,110주의 보통주를 2025-10-21가중평균 5.137달러의 가격으로 매수했습니다. 공시에는 거래가 4.96~5.20달러 범위의 가격으로 이뤄졌다고 기록되어 있습니다. 거래 후, 신고에 따르면 875,328주를 간접적으로 수익적으로 보유하게 되었습니다. 신고자의 관계란에 이사로 표시되어 있습니다.

공시는 주식이 Lynx1 Master Fund LP에 의해 보유되며, Lynx1 Capital Management LP가 투자 관리자로, 관리자의 일반 파트너의 유일한 구성원은 Weston Nichols이며, 일반적인 수익 소유권 면책 조항이 포함되어 있습니다.

Neuphoria Therapeutics Inc. (NEUP) a déclaré un achat d’initié dans le cadre d’un Formulaire 4. Les personnes déclarantes liées à Lynx1 Master Fund LP ont acheté 639 110 actions ordinaires le 21/10/2025 à un prix moyen pondéré de 5,137 USD. Le document indique que les transactions ont eu lieu sur des prix allant de 4,96 à 5,20 USD. Après la transaction, le document indique 875 328 actions détenues de manière bénéficiaire et indirecte. La case relation du déclarant indique Directeur.

Le document explique que les titres sont détenus par Lynx1 Master Fund LP, Lynx1 Capital Management LP en tant que gestionnaire d’investissement et Weston Nichols comme seul membre du partenaire général du gestionnaire, et comprend les clauses habituelles de divulgation de la propriété bénéficiaire.

Neuphoria Therapeutics Inc. (NEUP) hat einen Insiderkauf über ein Formular 4 offengelegt. Meldende Personen, verbunden mit Lynx1 Master Fund LP, kauften 639.110 Aktien Stammaktien am 21.10.2025 zu einem gewichteten Durchschnittspreis von 5,137 USD. Die Einreichung vermerkt, dass die Trades zu Preisen von 4,96 bis 5,20 USD stattfanden. Nach der Transaktion meldet die Einreichung 875.328 Aktien, die indirekt wohlerworbene Eigentümer sind. Das Beziehungsfeld des meldenden Persons gibt Direktor an.

Die Einreichung erklärt, dass die Wertpapiere von Lynx1 Master Fund LP gehalten werden, wobei Lynx1 Capital Management LP als Investmentmanager fungiert und Weston Nichols als einziges Mitglied des Generalpartners des Managers aufgeführt ist, und enthält übliche Hinweise zur vorteilhaften Eigentümerschaft.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lynx1 Capital Management LP

(Last) (First) (Middle)
D81 CALLE C, STE 301, PMB 1202

(Street)
DORADO PR 00646-2051

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Neuphoria Therapeutics Inc. [ NEUP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock, $0.00001 par value per share 10/21/2025 P 639,110 A $5.137(1) 875,328 I See footnote(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Lynx1 Capital Management LP

(Last) (First) (Middle)
D81 CALLE C, STE 301, PMB 1202

(Street)
DORADO PR 00646-2051

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Nichols Weston

(Last) (First) (Middle)
D81 CALLE C, STE 301, PMB 1202

(Street)
DORADO PR 00646-2051

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.96 to $5.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
2. The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.
Lynx1 Capital Management LP, By: Lynx1 Capital Management GP LLC, its general partner, By: /s/ Weston Nichols, Sole Member 10/23/2025
/s/ Weston Nichols 10/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Neuphoria Therapeutics (NEUP) report on this Form 4?

An insider-related group purchased 639,110 shares of common stock on 10/21/2025.

What was the price paid for the NEUP shares?

The filing reports a weighted average price of $5.137, with trades from $4.96 to $5.20.

How many NEUP shares are beneficially owned after the transaction?

The filing shows 875,328 shares beneficially owned on an indirect basis following the purchase.

Who holds the NEUP shares reported in the filing?

The securities are held by Lynx1 Master Fund LP, with Lynx1 Capital Management LP as investment manager.

Who is associated with the investment manager in the NEUP filing?

Weston Nichols is the sole member of the general partner of the investment manager, per the filing.

What relationship to Neuphoria is indicated in the Form 4?

The relationship box indicates Director for the reporting person.
Neuphoria Therapeutics Inc

NASDAQ:NEUP

NEUP Rankings

NEUP Latest News

NEUP Latest SEC Filings

NEUP Stock Data

11.43M
2.16M
0.53%
67.79%
2.58%
Biotechnology
Pharmaceutical Preparations
Link
United States
BURLINGTON